Ceftiofur (Excenel / Naxcel)

Ceftiofur is a third-generation cephalosporin antibiotic developed exclusively for veterinary use, making it one of the most important antimicrobial agents in modern livestock medicine. First described in 1987 and commercially available since the early 1990s, ceftiofur is manufactured and marketed by Zoetis under several brand names including Naxcel (ceftiofur sodium sterile powder), Excenel RTU EZ (ceftiofur hydrochloride ready-to-use suspension), Excede (ceftiofur crystalline free acid extended-release suspension), and the Spectramast line of intramammary products. The drug holds FDA approval for use in cattle, swine, sheep, goats, horses, dogs, and day-old poultry, representing one of the broadest species approvals of any veterinary antibiotic currently available.

As a member of the cephalosporin family, ceftiofur shares its fundamental mechanism of action with other beta-lactam antibiotics. The drug exerts its bactericidal effect by binding to penicillin-binding proteins located on the inner membrane of bacterial cell walls, thereby inhibiting the transpeptidation step essential for peptidoglycan cross-linking during cell wall synthesis. Without functional cell wall assembly, actively dividing bacteria undergo osmotic lysis and die. This mechanism makes ceftiofur most effective against bacteria that are actively growing and replicating, which is an important consideration when evaluating its therapeutic applications in clinical settings.

What distinguishes ceftiofur from earlier-generation cephalosporins is its enhanced spectrum of activity against gram-negative organisms while retaining meaningful gram-positive coverage. The drug demonstrates potent activity against the major respiratory pathogens of cattle and swine, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Actinobacillus pleuropneumoniae, and Streptococcus suis. Ceftiofur also possesses intrinsic resistance to degradation by many bacterial beta-lactamase enzymes, which gives it clinical utility against organisms that have developed resistance to older penicillins and first-generation cephalosporins. The drug's primary metabolite, desfuroylceftiofur, retains significant antibacterial activity and contributes to the overall therapeutic effect.

From a regulatory and public health standpoint, ceftiofur occupies a unique position as a critically important antimicrobial. Federal law in the United States restricts this drug to use by or on the order of a licensed veterinarian, and specific prohibitions exist against extra-label use for disease prevention purposes, at unapproved doses or frequencies, by unapproved routes of administration, and in unapproved major food-producing species or production classes. These restrictions reflect the importance of preserving cephalosporin efficacy in both human and veterinary medicine. Despite these regulatory constraints, ceftiofur remains one of the most widely used antibiotics in food animal production due to its favorable withdrawal profiles for meat and milk.

The approved indications for ceftiofur span multiple species and disease conditions, making it one of the most versatile antibiotics available to food animal practitioners. In cattle, the primary indication is the treatment of bovine respiratory disease (BRD), also known as shipping fever or pneumonia, caused by susceptible strains of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. BRD represents the most economically significant disease of feedlot cattle in North America, and ceftiofur serves as a first-line therapeutic option for many practitioners due to its broad-spectrum activity against the major BRD pathogens and its favorable pharmacokinetic profile in cattle.

Beyond respiratory disease, ceftiofur holds label approval for treating acute bovine interdigital necrobacillosis, commonly known as foot rot, caused by Fusobacterium necrophorum and Porphyromonas levii (formerly Bacteroides melaninogenicus). Foot rot causes significant lameness, production losses, and welfare concerns in both dairy and beef cattle. The drug is also approved for the treatment of acute post-partum metritis occurring within the first 14 days after calving in dairy cattle, addressing bacterial infections of the uterus that can compromise fertility and milk production. The Excede formulation additionally carries approval for metaphylactic use to control BRD in cattle at high risk of developing respiratory disease, such as newly arrived feedlot cattle.

In swine, ceftiofur is indicated for the treatment and control of swine respiratory disease (SRD), also called swine bacterial pneumonia, associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, Haemophilus parasuis, and Streptococcus suis. Respiratory disease in pigs causes substantial economic losses through mortality, reduced growth rates, and increased medication costs. The Excede formulation for swine provides the additional advantage of a single-dose treatment protocol, which reduces handling stress and labor requirements compared to multi-day injection regimens.

The Spectramast product line addresses mastitis in dairy cattle through two distinct formulations. Spectramast LC is an intramammary infusion approved for treating clinical mastitis in lactating dairy cattle caused by susceptible strains of coagulase-negative staphylococci, Streptococcus dysgalactiae, and Escherichia coli. Spectramast DC is formulated for treating subclinical mastitis at the time of dry-off. These intramammary applications deliver high concentrations of ceftiofur directly to the site of infection in the mammary gland.

Additional approved uses include the treatment of respiratory disease in sheep and goats, canine urinary tract infections caused by Escherichia coli and Proteus mirabilis, and the control of early mortality associated with E. coli infections in day-old chicks and turkey poults. Extra-label applications, while permitted under specific constraints, include the treatment of neonatal sepsis in calves, respiratory disease in camelids and cervids, and various infections in other species where the attending veterinarian determines that ceftiofur is the most appropriate therapeutic choice based on culture and sensitivity data.

Dosage regimens for ceftiofur vary by formulation, species, and indication, and strict adherence to label directions is essential both for therapeutic efficacy and regulatory compliance. For Naxcel (ceftiofur sodium sterile powder), the reconstituted product contains 50 mg ceftiofur per milliliter. In cattle, the recommended dosage is 0.5 to 1.0 mg ceftiofur per pound of body weight (1.1 to 2.2 mg/kg), administered by intramuscular or subcutaneous injection once daily for three to five consecutive days. The selection of dosage within this range should be based on the practitioner's assessment of disease severity, considering factors such as body temperature elevation, respiratory rate, appetite, and physical appearance.

For swine receiving Naxcel, the dosage is 1.36 to 2.27 mg ceftiofur equivalents per pound (3.0 to 5.0 mg/kg) of body weight, administered by intramuscular injection once daily for three consecutive days. Sheep, goats, and horses receive Naxcel by intramuscular injection at dosages determined by the treating veterinarian based on species-specific considerations and the nature of the infection. Naxcel requires reconstitution with sterile water prior to administration, and the reconstituted solution should be used within the timeframe specified on the product label. No vial closure should be entered more than 20 times.

Excenel RTU EZ (ceftiofur hydrochloride) offers the convenience of a ready-to-use formulation that does not require reconstitution. The product contains 50 mg ceftiofur equivalents per milliliter. Cattle dosing mirrors the Naxcel protocol at 0.5 to 1.0 mg ceftiofur equivalents per pound (1.1 to 2.2 mg/kg) daily for three to five days, administered intramuscularly or subcutaneously. Swine receive 1.36 to 2.27 mg ceftiofur equivalents per pound (3.0 to 5.0 mg/kg) by intramuscular injection daily for three days. The ready-to-use suspension must be shaken thoroughly before each use to ensure uniform drug distribution throughout the product.

Excede (ceftiofur crystalline free acid) represents a fundamentally different dosing approach, providing extended-release pharmacokinetics from a single injection. In cattle, a single subcutaneous injection of 6.6 mg ceftiofur equivalents per kilogram of body weight in the posterior aspect of the ear provides sustained therapeutic concentrations for treating BRD and controlling respiratory disease in high-risk cattle. The ear injection site is specified because the ear is removed during slaughter processing, eliminating concerns about injection site residues in edible tissues. For foot rot in cattle, the injection is administered subcutaneously at the base of the ear. The swine formulation of Excede is administered as a single intramuscular injection in the post-auricular region of the neck at 5.0 mg ceftiofur equivalents per kilogram of body weight.

The route of administration is critically important for both efficacy and safety. Intravenous injection of ceftiofur crystalline free acid has been associated with fatal reactions and must never be performed. For injectable formulations administered intramuscularly, the preferred injection site is the neck region, which minimizes carcass damage from potential injection site reactions. No more than 10 to 15 milliliters should be administered per injection site depending on the product and species. Proper needle selection, aseptic technique, and appropriate animal restraint are essential components of safe and effective ceftiofur administration.

Withdrawal times for ceftiofur products are among the most favorable of any antibiotic used in food-producing animals, which is a major factor in the drug's widespread adoption in both dairy and beef operations. However, these withdrawal periods vary by formulation and must be followed precisely to avoid illegal residues in meat and milk. Failure to observe established withdrawal times violates federal law and can result in regulatory action against both the producer and the prescribing veterinarian.

For Naxcel (ceftiofur sodium) used according to label directions in cattle, there is no milk discard time required and no pre-slaughter withdrawal period established for meat. This zero-day milk withdrawal makes Naxcel particularly valuable in lactating dairy cattle, where discarding milk represents a direct economic loss. The absence of a meat withdrawal period allows maximum flexibility in marketing decisions for beef cattle. However, these favorable withdrawal times apply only when the product is used at label dosages and by approved routes. Extra-label use may result in prolonged tissue residues that cannot be predicted by the standard withdrawal times.

Excenel RTU EZ (ceftiofur hydrochloride) carries a four-day pre-slaughter withdrawal for cattle and a four-day withdrawal for swine when injection site volumes do not exceed five milliliters. No milk discard time is required for dairy cattle receiving Excenel at label dosages. These short withdrawal periods facilitate treatment of animals relatively close to marketing without extended holding periods. The product is not approved for use in pre-ruminating calves intended for veal processing.

Excede (ceftiofur crystalline free acid) has a 13-day pre-slaughter withdrawal period for cattle and a 14-day withdrawal for swine. The longer withdrawal for Excede reflects the extended-release pharmacokinetics of the crystalline free acid formulation, which maintains therapeutic drug concentrations for a prolonged period after injection. No milk discard time is required for Excede in dairy cattle. The restriction on injection site placement to the base of the ear in cattle further minimizes the risk of detectable residues in edible tissues.

The Spectramast intramammary products have their own withdrawal specifications. Spectramast LC (lactating cow formulation) requires a milk discard period of 72 hours (six milkings at 12-hour intervals) following the last treatment, and treated cows must not be slaughtered for two days after the last treatment. Spectramast DC (dry cow formulation) should not be used within 30 days of calving, and cows must not be slaughtered within 16 days of treatment. Understanding and observing these product-specific withdrawal times is essential for maintaining the safety of the food supply and complying with federal regulations governing antibiotic use in food animals.

Ceftiofur is generally well-tolerated across all approved species when administered according to label directions, and serious adverse reactions are uncommon. The most frequently observed side effects are local tissue reactions at injection sites, which is consistent with the pharmacological properties of injectable antibiotic formulations. Understanding the expected side effect profile helps veterinarians and producers distinguish routine post-treatment responses from genuinely concerning adverse events that may require clinical attention.

Injection site reactions represent the most common adverse effect across all injectable ceftiofur formulations. Transient swelling, firmness, and discoloration at the injection site have been documented in cattle, swine, and other species. With Naxcel administered subcutaneously to cattle, studies have shown that areas of yellow-red discoloration spanning several square centimeters can persist beyond four and a half days following a single injection. Occasional abscess formation at injection sites has also been reported. These local reactions are generally self-limiting and resolve without specific treatment, though they underscore the importance of proper injection technique and site selection to minimize tissue damage.

Gastrointestinal disturbances, particularly mild and transient diarrhea, have been reported as a potential adverse effect of ceftiofur administration. As with all broad-spectrum antibiotics, ceftiofur can alter the normal gastrointestinal flora, which may result in changes in fecal consistency or frequency. In most cases, these effects are mild and resolve spontaneously after treatment completion. More significant gastrointestinal complications are rare but should be monitored, particularly in animals receiving extended courses of therapy or those with pre-existing digestive conditions.

Hypersensitivity reactions are possible with ceftiofur, as with all beta-lactam antibiotics including penicillins and other cephalosporins. Animals with a known history of hypersensitivity to any beta-lactam antibiotic should not receive ceftiofur. Cross-reactivity between penicillins and cephalosporins has been documented, though its true incidence in veterinary patients is difficult to establish. Anaphylactic reactions, while extremely rare, can be life-threatening and require immediate emergency treatment. Persons handling ceftiofur products who have known sensitivities to beta-lactam antibiotics should take precautions to avoid direct skin contact, as allergic reactions in sensitized individuals have been reported following occupational exposure.

Safety studies in cattle and swine have demonstrated that ceftiofur possesses a wide margin of safety. Tolerance studies in feeder pigs showed no overt signs of toxicity when the drug was administered at more than 25 times the highest recommended daily dosage for five consecutive days. Similarly, safety studies administering up to five times the recommended dose for five times the recommended duration revealed no clinically significant systemic toxicity. The primary concern at elevated doses remains the severity of local injection site reactions rather than systemic toxicity. However, it must be emphasized that intravenous administration of ceftiofur crystalline free acid (Excede) has been associated with fatalities and is strictly contraindicated.

Ceftiofur, like other cephalosporin antibiotics, has a relatively limited number of clinically significant drug interactions in veterinary species. However, practitioners should be aware of known interactions and contraindications to ensure safe and effective use. The most fundamental contraindication applies to any animal with a documented history of hypersensitivity to ceftiofur or other beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems. Cross-reactivity within the beta-lactam class is an established phenomenon, and animals that have experienced allergic reactions to any member of this drug family should receive alternative antimicrobial therapy.

Concurrent use of ceftiofur with bacteriostatic antibiotics such as tetracyclines, macrolides, or chloramphenicol is generally discouraged based on pharmacological principles. Ceftiofur exerts its bactericidal effect by disrupting cell wall synthesis in actively dividing bacteria, while bacteriostatic agents inhibit bacterial protein synthesis and slow or halt bacterial growth. The theoretical concern is that slowing bacterial division reduces the number of actively growing organisms available for ceftiofur to kill, potentially diminishing its bactericidal activity. While clinical evidence of this antagonistic interaction is limited in veterinary patients, the theoretical basis is well-established and most practitioners avoid these combinations when possible.

Nephrotoxic agents should be used cautiously in combination with ceftiofur. Although ceftiofur itself has relatively low nephrotoxic potential compared to aminoglycoside antibiotics, the combination of cephalosporins with known nephrotoxic drugs such as aminoglycosides (gentamicin, amikacin) or certain non-steroidal anti-inflammatory drugs may increase the risk of kidney damage, particularly in dehydrated animals or those with pre-existing renal compromise. When combination therapy with an aminoglycoside is deemed necessary, adequate hydration status should be maintained and renal function monitored where feasible.

Regulatory contraindications are as important as pharmacological ones for ceftiofur in food-producing animals. Federal law prohibits the extra-label use of ceftiofur for disease prevention purposes, at unapproved doses, frequencies, or durations, by unapproved routes of administration, and in unapproved major food-producing species or production classes. These restrictions are more stringent than those applied to many other veterinary antibiotics and reflect the classification of third-generation cephalosporins as critically important antimicrobials by the World Health Organization. Ceftiofur is not approved for use in calves intended for veal processing, and practitioners must comply with all applicable regulations when prescribing this drug.

The effects of ceftiofur on bovine and swine reproductive performance have not been fully determined, and caution is advised when treating pregnant animals. While clinical experience suggests that ceftiofur is used routinely in pregnant livestock without apparent adverse reproductive effects, controlled reproductive safety studies are limited. The decision to treat pregnant animals should weigh the benefits of controlling bacterial infection against the theoretical risks of antimicrobial administration during gestation. Ceftiofur is widely used for treating acute post-partum metritis in dairy cattle, indicating that the drug is considered acceptably safe during the immediate post-calving period.

Proper storage and handling of ceftiofur products are essential for maintaining drug potency, ensuring therapeutic efficacy, and protecting the safety of personnel who administer the medication. Each ceftiofur formulation has specific storage requirements dictated by the chemical stability of its particular salt form and vehicle composition. Failure to follow storage guidelines can result in degradation of the active ingredient, reduced antimicrobial potency, and potentially harmful breakdown products.

Naxcel (ceftiofur sodium) sterile powder should be stored at controlled room temperature prior to reconstitution. The dry powder is relatively stable in its unreconstituted form and has a shelf life determined by the manufacturer's expiration dating. Once reconstituted with sterile water for injection, the resulting solution must be refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and used within the timeframe specified on the product label, typically seven days for refrigerated storage or 12 hours at room temperature. The reconstituted solution should be protected from light and inspected visually for particulate matter or discoloration before each use. Any unused reconstituted solution remaining after the specified storage period must be discarded.

Excenel RTU EZ (ceftiofur hydrochloride) ready-to-use suspension should be stored at controlled room temperature between 20 and 25 degrees Celsius (68 to 77 degrees Fahrenheit). The suspension should be shaken vigorously for at least 90 seconds to ensure complete resuspension before withdrawing each dose. Settling of the active ingredient is normal during storage, but thorough agitation is critical for delivering consistent, accurate doses. The product should be protected from freezing and excessive heat, and vials should be inspected for any signs of contamination or physical changes before use.

Excede (ceftiofur crystalline free acid) sterile suspension requires shaking before use and should be stored according to label specifications. The crystalline free acid formulation is designed to form a depot at the injection site that slowly releases active drug over an extended period. Proper suspension of the crystals through adequate shaking is essential for consistent drug delivery and extended-release performance. Improper storage conditions that cause crystal aggregation or formulation separation may compromise the extended-release characteristics of the product.

Personnel handling any ceftiofur product should take precautions to avoid direct skin and mucous membrane contact. Beta-lactam antibiotics including cephalosporins can cause allergic reactions in sensitized individuals, and repeated occupational exposure may lead to sensitization in previously non-allergic persons. Protective gloves should be worn during product preparation and administration. If accidental skin contact occurs, the affected area should be washed immediately with soap and water. In the event of accidental self-injection, immediate medical attention should be sought, and the treating physician should be informed that the product contains a cephalosporin antibiotic. Used needles, syringes, and empty containers should be disposed of in accordance with local regulations governing pharmaceutical waste.

The responsible use of ceftiofur in food animal production is inextricably linked to broader concerns about antimicrobial resistance and the preservation of cephalosporin efficacy across both veterinary and human medicine. Third-generation cephalosporins are classified as critically important antimicrobials by the World Health Organization, meaning that resistance development in animal bacteria has potential implications for human health. This classification has driven regulatory restrictions on ceftiofur use and placed additional responsibilities on veterinary practitioners who prescribe the drug.

Resistance to ceftiofur among animal pathogens has been documented and represents an evolving concern for veterinary medicine. Escherichia coli strains with resistance to ceftiofur have been identified in cattle, swine, and poultry. The primary mechanisms of resistance involve the production of extended-spectrum beta-lactamases (ESBLs) or AmpC-type beta-lactamases that can hydrolyze the ceftiofur molecule. These resistance genes are frequently carried on mobile genetic elements such as plasmids and integrons, which facilitates horizontal transfer of resistance between bacterial species and across different animal populations. Monitoring resistance trends through surveillance programs is essential for guiding empirical therapy decisions and identifying emerging resistance patterns.

Prudent use guidelines for ceftiofur emphasize several core principles designed to minimize resistance selection pressure. The drug should be used only for the treatment of diagnosed bacterial infections or, in the case of approved metaphylactic applications, for the control of disease in populations at documented high risk. Ceftiofur should not be used as a mass medication strategy, as a growth promotant, or as a substitute for proper animal husbandry and biosecurity practices. Treatment decisions should be informed by culture and susceptibility testing whenever practical, particularly in cases of treatment failure or recurrent infections. Using the drug at full labeled doses for the complete recommended duration helps ensure that bacterial populations are adequately exposed to bactericidal concentrations, reducing the selection advantage of partially resistant organisms.

The regulatory framework surrounding ceftiofur use reflects these resistance concerns. The prohibition on extra-label use for disease prevention, at unapproved doses or durations, and by unapproved routes is specifically designed to limit selection pressure for resistance. Veterinarians who prescribe ceftiofur bear responsibility for ensuring that its use is justified by a valid veterinary-client-patient relationship, that clients understand and comply with labeled directions, and that treated animals are properly identified and withdrawal times observed. Ongoing surveillance of ceftiofur susceptibility among target pathogens informs both individual treatment decisions and broader policy discussions about the continued availability and appropriate use of this critically important antibiotic class.

Producers and veterinarians should view ceftiofur as a valuable but finite resource that requires careful stewardship. Implementing comprehensive herd health programs that emphasize disease prevention through vaccination, nutrition, biosecurity, and stress reduction can decrease the overall need for antibiotic therapy and thereby reduce selection pressure for resistance. When ceftiofur is indicated, its use should be targeted, justified, and documented as part of a broader antimicrobial stewardship program that preserves the drug's efficacy for future generations of both animals and the practitioners who treat them.

While ceftiofur holds broad multi-species approval, the practical aspects of its use differ significantly across the various farm animal species for which it is indicated. Understanding species-specific pharmacokinetics, disease presentations, and management contexts is essential for veterinarians and producers seeking to optimize therapeutic outcomes. Each approved species presents unique challenges and opportunities for ceftiofur therapy that merit individual consideration.

In beef cattle, ceftiofur use is dominated by the treatment and metaphylaxis of bovine respiratory disease in feedlot settings. Newly arrived cattle that have endured the stresses of weaning, transportation, commingling, and dietary change are at elevated risk for BRD, and ceftiofur is frequently included in arrival processing protocols. The Excede formulation is particularly suited to feedlot applications because its single-dose, extended-release design eliminates the need for repeated daily injections and the associated animal handling stress. For individual treatment of clinically ill cattle, either Naxcel or Excenel RTU EZ may be selected based on practitioner preference, with treatment decisions guided by clinical response over the three to five day treatment course.

Dairy cattle applications for ceftiofur differ markedly from beef cattle use patterns. The zero-day milk withdrawal for Naxcel and Excenel makes these products especially attractive for treating respiratory disease, foot rot, and metritis in lactating cows, where milk discard represents a direct economic penalty. The Spectramast intramammary products address mastitis, which is the most costly disease affecting the dairy industry worldwide. Decisions about mastitis treatment with ceftiofur should be informed by herd-level pathogen and resistance surveillance data, as the causative organisms and their susceptibility profiles vary considerably among dairy operations.

Swine applications of ceftiofur focus primarily on respiratory disease complexes involving multiple bacterial pathogens. The intensive housing conditions typical of modern swine production create environments where respiratory pathogens can spread rapidly through populations. The Excede formulation for swine allows single-dose treatment, which is advantageous in large-scale swine operations where repeated individual animal handling is logistically challenging. The intramuscular route specified for swine differs from the subcutaneous route preferred in cattle, and injection site selection in the neck region minimizes carcass defects at slaughter. Sheep and goats represent important but less extensively studied species for ceftiofur use. While Naxcel carries label approval for intramuscular injection in sheep and goats, fewer controlled clinical trials have been conducted in small ruminants compared to cattle and swine. Extra-label use considerations frequently arise in small ruminant practice because fewer products are specifically labeled for these species. Ceftiofur is commonly used in sheep and goat operations for respiratory disease, neonatal infections, and foot rot, with dosages extrapolated from cattle data or based on published pharmacokinetic studies in small ruminants. The drug may be used in lactating dairy sheep and goats, extending the same milk safety advantages observed in dairy cattle.

Poultry applications of ceftiofur are limited to the subcutaneous injection of day-old chicks and turkey poults for the control of early mortality associated with susceptible E. coli organisms. The dosage for day-old chicks is 0.08 to 0.20 mg ceftiofur per chick, delivered as a subcutaneous injection using specialized equipment capable of delivering the small volumes required. This application is unique among ceftiofur uses in that it targets neonatal birds rather than growing or adult animals, and its value lies in reducing first-week mortality in commercial poultry operations where E. coli is an identified problem.

The pharmacokinetic profile of ceftiofur is central to understanding its clinical utility and forms the scientific basis for approved dosage regimens across species. Following parenteral administration, ceftiofur is rapidly and extensively metabolized to its primary active metabolite, desfuroylceftiofur, which retains antimicrobial activity equivalent to the parent compound. Desfuroylceftiofur subsequently binds reversibly to plasma proteins, predominantly albumin, creating a reservoir of protein-bound drug that is released gradually as free drug is eliminated. This protein binding behavior extends the effective duration of antimicrobial activity beyond what would be predicted from free drug concentrations alone.

Absorption characteristics differ substantially among the three commercially available salt forms. Ceftiofur sodium (Naxcel) is rapidly absorbed following intramuscular injection, reaching peak plasma concentrations within one to two hours. The relatively short duration of therapeutic concentrations necessitates once-daily dosing for three to five consecutive days. Ceftiofur hydrochloride (Excenel RTU EZ) has absorption kinetics similar to the sodium salt, also requiring daily administration over a multi-day treatment course. In contrast, ceftiofur crystalline free acid (Excede) is specifically designed for sustained release from the injection site, providing therapeutic concentrations for extended periods following a single injection. The crystalline structure of the free acid dissolves slowly at the injection depot, maintaining prolonged drug absorption and eliminating the need for repeated injections.

Distribution studies demonstrate that ceftiofur and its active metabolites achieve effective concentrations in the tissues and body fluids most relevant to its therapeutic indications. In cattle with BRD, the drug penetrates into pulmonary tissues and bronchial secretions at concentrations that exceed the minimum inhibitory concentrations for target respiratory pathogens. Distribution into synovial fluid, interdigital tissues, and uterine fluids supports the drug's efficacy against foot rot and metritis. The volume of distribution is moderate, reflecting the drug's significant protein binding, and tissue concentrations generally parallel plasma concentrations with some compartmental delay.

Elimination of ceftiofur metabolites occurs primarily through renal excretion, with smaller contributions from biliary elimination and fecal excretion. The elimination half-life of total antimicrobial activity (parent drug plus active metabolites) is longer than would be predicted from the parent compound alone, due to the slow release of desfuroylceftiofur from plasma protein binding sites. In cattle, the terminal elimination half-life for total antimicrobial activity ranges from approximately 10 to 14 hours for the sodium and hydrochloride salts, supporting once-daily dosing. For the crystalline free acid formulation, the absorption-limited pharmacokinetics result in an apparent half-life that reflects the slow dissolution and absorption from the injection depot rather than true systemic elimination.

As a time-dependent antibiotic, the clinical efficacy of ceftiofur correlates most strongly with the duration of time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the target pathogen. This pharmacodynamic parameter, known as the time above MIC or T>MIC, is the most predictive index of bacteriological and clinical cure for cephalosporin antibiotics. Dosage regimens are designed to maintain T>MIC for at least 60 to 70 percent of the dosing interval against susceptible organisms. This pharmacokinetic-pharmacodynamic relationship explains why adequate dosing and full treatment courses are essential for therapeutic success and why sub-therapeutic exposure promotes the selection of resistant bacterial subpopulations.